2-amino-2-ethylpropanediol

Carcinogenicity

Description of key information

Based on all available data of the substances within the chemical category, the weight of evidence demonstrates that the substances in this chemical category seem highly unlikely to be carcinogenic and are not classifiable as carcinogens. Further testing is not required under Regulation (EC) 1907/2006, Annex XI, section 1.2.

Justification for classification or non-classification

Based on all available data of the substances within the chemical category, it is expected that AEPD has no carcinogenic potential. The available data do not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and

are therefore conclusive but not sufficient for classification.

Additional information

There are no animal data available on the carcinogenicity or chronic toxicity of 2-amino-2-ethyl-1,3-propanediol (AEPD) or within the chemical category AEPD belongs to. The members of the category of 2-amino-1,3- propane-diols are substances that share a common propane backbone with an amine group at 2-carbon position and primary alcohols at 1 and 3 positions. The following substances are thus members of the aminopropanediol category: 2-amino-2-ethyl-1,3-propanediol (AEPD, CAS No. 115-70-8), 2-amino-2-methyl-1,3-propane-diol (AMPD, CAS No. 115-69-5), 2-amino-1,3-propanediol (APD, CAS No. 534-03-2) and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol, CAS No. 77-86-1) The only structural difference between trometamol and AEPD is a replacement of a hydroxyl group with a methyl group. Further analogues differ in the length of the alkyl side-chain at position 2 so that the following sequence is obtained: from 0 carbon atoms (APD) through 1 (AMPD) to 2 (AEPD). There are no other functional groups present in these molecules.  

 

The modelling of potential metabolites via the OECD QSAR toolbox v.2.0 (2010) did not predict relevant metabolites of the category members. Based on the chemical structure of the parental compounds, no metabolism is expected. Therefore, it can be assumed that aminopropanediols will not show reactive properties under in vitro and in vivo test conditions. All the category members are of low concern with regard to systemic toxicity. Available studies via the oral, dermal and intraperitoneal route indicate low acute and repeated dose toxicity. Inhalation is of no concern, because the low vapour pressure means that exposure is unlikely to occur. The results of the acute studies, as well as the repeated dose studies, demonstrate that the main cause of toxicity was the intrinsic alkalinity of the category members at the site of contact. The Cramer classification (related mainly to the oral route) also indicates a low toxicological concern for all the category members. No metabolism by cytochrome P450 enzymes in-vivo is expected; this is supported by predictions from QSAR modelling. Furthermore, all the category members were not mutagenic or clastogenic in the available genetic toxicity studies, bear no structural similarity to known carcinogens, have no functional groups associated with carcinogenicity and did not produce evidence of neoplasia in repeated dose toxicity studies. Therefore it is concluded that the category members do not possess a carcinogenic potential.